Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott Joseph Antonia, Hossein Borghaei, Suresh S. Ramalingam et al. · The Lancet Oncology · 2019
Cited by 351 works. doi:10.1016/s1470-2045(19)30407-3
Authors
- Scott Joseph Antonia
- Hossein Borghaei
- Suresh S. Ramalingam
- Leora Horn
- Javier de Castro
- Adam Płużański
- Marco Angelo Burgio
- Marina Chiara Garassino
- Laura Q.M. Chow
- Scott N. Gettinger
- Lucio Crinò
- David Planchard
- Charles Andrew Butts
- Alexander Edward Dela Cruz Drilon
- Joanna Wójcik-Tomaszewska
- Gregory A. Otterson
- Shruti Agrawal
- Ang Li
- John R. Penrod
- Julie Renee Brahmer
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- SEER Cancer Statistics Review, 1975-2003
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Analysis of survival by tumor response.